Last reviewed · How we verify
Type 1 Gaucher disease
Approved treatments
- Elelyso · Pfizer Inc.
Recombinant glucocerebrosidase enzyme replacement therapy that catalyzes hydrolysis of glucocerebroside to glucose and ceramide.
Clinical guidelines
- FDA label — 1L
ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Type 1 Gaucher disease patent landscape — cliff calendar, originator estates, attackable patents
- Type 1 Gaucher disease treatment landscape brief
- Type 1 Gaucher disease treatment updates RSS
Frequently asked questions about Type 1 Gaucher disease
What drugs treat Type 1 Gaucher disease?
Tracked treatments include Elelyso.
What is the treatment for Type 1 Gaucher disease?
Standard treatment for Type 1 Gaucher disease includes Elelyso. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Type 1 Gaucher disease?
FDA label publishes guidelines for Type 1 Gaucher disease. 1 guideline references tracked.
Related
- Treatment landscape: Type 1 Gaucher disease patent cliff · Type 1 Gaucher disease CI report
- Treatment: Elelyso · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing